Innervace
Innervace: Developing implantable, tissue-engineered solutions for neurodegenerative disorders since 2018.
Founded
2018Innervace: Developing implantable, tissue-engineered solutions for neurodegenerative disorders since 2018.
Innervace, founded in 2018, is a regenerative therapy company dedicated to developing implantable, tissue-engineered solutions for neurodegenerative disorders. The company's core mission is to create anatomically inspired living scaffolds for brain pathway reconstruction, with a vision to revolutionize treatment for conditions like Parkinson's disease. Innervace's lead clinical product is a tissue-engineered nigrostriatal pathway designed to mimic the lost connections in patients with Parkinson's, aiming to restore functionality and improve quality of life.
Notable affiliated individuals include leading scientists and medical professionals specializing in neurodegenerative diseases. The company has garnered significant attention and investment from key players in the biotech and medical fields. Among its achievements, Innervace has successfully advanced its pre-clinical trials and is on the path to initiating clinical trials. The overall impact of Innervace lies in its potential to offer groundbreaking treatments that could significantly alter the landscape of neurodegenerative disease management.
Companies similar to Innervace include Convalesce, Regennova, Enterin and Renerva.
Innervace was founded in 2018.
Innervace's headquarters is located in New York City, NY, US.
Innervace's most recent funding round was for $40M (USD) in September 2022.
As of Sep 8, 2022, Innervace has disclosed funding of $40M (USD). Undisclosed round amounts are excluded.
Innervace has 7 employees as of Feb 5, 2024.
Renerva
renerva.com
